Translating Clinical Evidence forSensor-Based Glucose Monitoring and Technological Innovations to the Front Lines of Clinical Practice
Estimated Time to Complete Educational Activity
In this web-based program, physicians will learn how recent developments in sensor-based continuous glucose monitoring have advanced the management of Type 1 and Type 2 diabetes.
March 22, 2019
March 22, 2021
Method of Physician Participation Utilized in Learning Process
There are no fees for participating and receiving CME credit for this activity. During the period March 22, 2019 to March 22, 2021 participants must:
1) read the learning objectives and faculty disclosures;
2) study the educational activity, and are expected to view all 6 segments totaling 1.5 hours to successfully complete the activity and earn CME credit;
3) register and complete the evaluation form and post-test;
4) score 100% on the post-test; and
5) print out your CME certificate.
Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.
Supported by an educational grant from Abbott.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physician.
Credit Designation Statement
The University of Massachusetts Medical School designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Policy on Faculty & Provider Disclosure
The University of Massachusetts Medical School requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to The University of Massachusetts Medical School policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCM.
Program Faculty and Disclosure
Professor Dr. Jochen Seufert, MD, PhD
Professor of Internal Medicine, Endocrinology and Diabetology
Director or the Division of Endocrinology and Diabetology
Medical Centre of the University of Freiburg
Speaker’s Bureau: Abbott, Astra Zeneca, Boehringer Ingelheim, Lilly, MedScape, Novartis, NovoNordisk, Sanofi Aventis
Advisory Board: Abbott, Astra Zeneca, Boehringer Ingelheim, GI-Dynamics, Janssen, Lilly, Mundipharma, NovoNordisk, Sanofi Aventis
Research Support: Astra Zeneca, Boehringer Ingelheim, GI-Dynamics, Intarcia, Ipsen, Janssen, Novartis, NovoNordisk, Sanofi Aventis, Ypsomed
Professor Gerry Rayman, MD, FRCP
Professor, University of East Anglia, University of Suffolk, University of Cambridge
Consultant Physician and Diabetologist
Ipswich Hospital NHS Trust
Head of Service at the Diabetes and Endocrine Centre
Ipswich Hospital NHS Trust
Ipswich, United Kingdom
Honoraria/Expenses: Abbott, Bayer, Boehringer Ingelheim, Eli Lilly, NovoNordisk, Sanofi Aventis
Consulting/Advisory: Abbott, Bayer, Boehringer Ingelheim, Eli Lilly, NovoNordisk, Sanofi Aventis
Grant/Research Support: Honoraria/Expenses: Abbott, Bayer, Eli Lilly, NovoNordisk, Sanofi Aventis
Ramzi Ajjan, MD, PhD, FRCP
Associate Professor/Consultant in Diabetes and Endocrinology
Regional CRN Lead for Metabolic and Endocrine Research
University of Leeds and Leeds Teaching Hospitals Trust
Leeds, United Kingdom
Consultant and Research Support: Abbott Diabetes Care
Upon completion of the proposed program activities, physicians will be able to:
- Outline and discuss the evidentiary basis for senor/patch-based CGM technologies, and how to best Implement CGM-based technologies into their overall diabetes care plans for patients with T1D and T2D.
- Analyze the rationale and evidence for recommending and facilitating adoption of technology-centric CGM monitoring and treatment plans using patch-and-reader-based technologies.
- Compare and contrast available CGM-facilitating monitoring technologies and pair such technologies with optimal patient profiles.
- Educate patients with diabetes about the rationale, evidence, and outcome- optimizing results associated with technology-based, patient-centric and physician-directed CGM monitoring strategies that can be used to effect optimal lifestyle, diet-, and pharmacology-based approaches to attaining guideline-based HA1c levels in patients with T1d and T2D.
- Identify which patients with diabetes are ideal candidates for a technology-based, patient-directed glucose monitoring system.
- Interpret and apply data and results from clinical trials and experts with experience in CGM-facilitating monitoring technologies to improve patient care, improve safety of drug therapy for T1D and T2D, detect and mitigate risk of hypoglycemia, improve patient- and physician-directed changes in antidiabetic therapy, reinforce the safe use of antidiabetic drugs, and facilitate patient-activated drug titration, glycemic monitoring and disease management.
- Translate landmark clinical studies focused on CGM-based technologies to the front lines of clinical practice in the diabetes and primary care setting; and understand the translational implications of deploying sensor-based, CGM-based technologies as a foundational approach to improving outcomes in patients across the spectrum of diabetes.
- Educate other clinical providers on the diabetes care team about the rationale, role, evidence, and outcome-enhancing results that are derived from employing technology-based CGM strategies—both patient- and physician-directed—across the broad spectrum of patients with diabetes.
Hardware and Software Requirements:
To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.
When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:
- We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
- For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
- We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
- If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.